- Home
- GILD vs PANW Comparison
GILD vs PANW Comparison
Compare GILD & PANW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GILD | PANW |
|---|---|---|
| Founded | 1987 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Computer peripheral equipment |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 168.6B | 173.3B |
| IPO Year | 2003 | 2012 |
Fundamental Metrics
Financial Performance| Metric | GILD | PANW |
|---|---|---|
| Price | $129.55 | $271.87 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 18 | 39 |
| Target Price | $148.39 | ★ $216.28 |
| AVG Volume (30 Days) | 5.5M | ★ 9.0M |
| Earning Date | 05-07-2026 | 05-19-2026 |
| Dividend Yield | ★ 2.55% | N/A |
| EPS Growth | ★ 1684.21 | N/A |
| EPS | ★ 1.61 | 0.79 |
| Revenue | ★ $24,689,000,000.00 | $2,273,100,000.00 |
| Revenue This Year | $4.68 | $24.93 |
| Revenue Next Year | $6.04 | $19.97 |
| P/E Ratio | ★ $80.23 | $353.56 |
| Revenue Growth | 9.98 | ★ 29.04 |
| 52 Week Low | $107.19 | $139.57 |
| 52 Week High | $157.29 | $302.95 |
Technical Indicators
Market Signals| Indicator | GILD | PANW |
|---|---|---|
| Relative Strength Index (RSI) | 43.90 | 64.09 |
| Support Level | $128.33 | $179.81 |
| Resistance Level | $137.35 | N/A |
| Average True Range (ATR) | 3.01 | 12.98 |
| MACD | -0.18 | 0.34 |
| Stochastic Oscillator | 27.44 | 53.54 |
Price Performance
Historical ComparisonAbout GILD Gilead Sciences Inc.
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
About PANW Palo Alto Networks Inc.
Palo Alto Networks is a platform-based cybersecurity vendor with product offerings covering network security, cloud security, and security operations. The California-based firm has more than 80,000 enterprise customers across the world, including more than three-fourths of the Global 2000.